Post Archives
Visitor Survey

Visitor Survey

Link PDF: Autoantibodies associated with diseases of the CNS: new developments and future challenges

Several CNS disorders associated with specifi c antibodies to ion channels, receptors, and other synaptic proteins have been recognised over the past 10 years, and can be often successfully treated with immunotherapies. Antibodies to components of voltage-gated potassium channel complexes (VGKCs), NMDA receptors (NMDARs), AMPA receptors (AMPARs), GABA type B receptors (GABABRs), and glycine receptors (GlyRs) can be identifi ed in patients and are associated with various clinical presentations, such as limbic encephalitis and complex and diff use encephalopathies. These diseases can be associated with tumours, but they are more often non-paraneoplastic, and antibody assays can help with diagnosis. The new specialty of immunotherapy-responsive CNS disorders is likely to expand further as more antibody targets are discovered. Recent fi ndings raise many questions about the classifi cation of these diseases, the relation between antibodies and specifi c clinical phenotypes, the relative pathological roles of serum and intrathecal antibodies, the mechanisms of autoantibody generation, and the development of optimum treatment strategies.

This article by Angela Vincent, Christian Bien, Sarosh Irani, and Patrick Waters talks about conditions of the CNS caused by autoantibodies. The full paper can be found at This was posted to thread on 27th October, 2014 by G.D.

Copyright © The Lancet 2011 | Authors Angela Vincent, Christian Bien, Sarosh Irani, and Patric Waters

This website is not a substitute for independent professional advice. Nothing contained in this site is intended to be used as medical advice. No articles, personal accounts, or other content are intended to be used to diagnose, treat, cure or prevent any disease, nor should it be used for therapeutic purposes or as a substitute for your own health professionals advice.